4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

Prospective, Randomized, Placebo-controlled, Phase 2 Study of 4-aminopyridine, Atenolol, or Placebo in the Treatment of Patients With Vestibular Migraine

This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on study.

Inclusion Criteria:

• Severe vestibular migraine (VM)

Exclusion Criteria:

• Neurologic or otologic disease other than VM
• Psychiatric illness requiring medication
• Medical illness including cancer, coronary artery or cerebrovascular disease
• Known allergy to one of the test medications
• Contraindication to use of one of the test medications - asthma, symptomatic hypotension, history of seizures
• Taking migraine prophylactic medication or vestibular suppressants.
• Pregnant or breast feeding women